Industry
Featured experience
Novo Nordisk acquisition of certain Catalent sites from Novo Holdings
We are advising Novo Nordisk on the acquisition
AbbVie $15 billion senior notes offering
The investment-grade offering comprised seven tranches
Auna $360 million U.S. IPO
We advised Auna on its U.S. IPO and NYSE listing
Trial victory in patent infringement case for Magnolia Medical Technologies
We served as lead trial counsel for Magnolia Medical in an action against its sole competitor
Johnson & Johnson $16.6 billion acquisition of Abiomed
We are advising J.P. Morgan Securities as financial adviser to Johnson & Johnson
Recursion Pharmaceuticals $150 million private placement
We advised the placement agents on the private placement of common stock
Prime Medicine $175 million IPO
The shares are listed on the Nasdaq Global Market
Denali Therapeutics $316 million follow-on offering
The shares are listed on the Nasdaq Global Select Market
European Biotech Acquisition $200 million combination with Oculis
We are advising European Biotech Acquisition Corp. on its deSPAC transaction
Immatics $110 million follow-on offering
We advised Immatics on the offering of shares
Gamida Cell $20 million follow-on offering
The shares are listed on the Nasdaq Global Select Market
Solid Biosciences $75 million common stock PIPE offering
The financing is taking place concurrently with the company’s acquisition of AavantiBio
EDAP TMS $23 million follow-on offering
The ADSs are listed on the Nasdaq Global Market
InnoCare Pharma RMB2.9 billion Shanghai IPO
This is the largest A-share listing by an overseas-listed biotechnology company in 2022 so far